Beneath these individual data points, a single formation is becoming visible: the field is crossing a protocol threshold. The era of early-access optimism — when trial design could afford ambiguity about washout periods, cardiac monitoring, and drug interaction management — is closing. What is forming in its place is a more demanding regulatory environment that will slow some programs while permanently elevating the floor for all of them. The SSRI interaction question is not a footnote; it touches the enrollment eligibility of a significant fraction of the depression and PTSD patients these trials are designed to serve. The ibogaine cardiac guidance, when it arrives — and the signal density now makes its arrival near-certain by mid-2027 — will not kill the program. It will force the field to choose its best candidate, and that candidate is increasingly oxa-noribogaine. The analog pathway is not a retreat from ibogaine's promise; it is the form that promise takes when it is serious about arriving.
The people inside this story are veterans in their fifties sitting in living rooms where the news still cycles through the same impossibilities — another pill that dulls without healing, another waitlist, another year. They have heard about ibogaine in Mexico and they have heard about the heart risks. They have heard that a Stanford trial showed real numbers. What they are feeling today is something that has no clean name: hope that has learned to be careful. The highest positive outcome available to them from the current moment is not faster access to an under-monitored compound — it is a protocol that is genuinely safe enough to reach them at scale, inside a system that can hold what they carry. That protocol is forming now. It is being written, slowly, in exactly the kind of data that accumulated this week.
The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new.
The future does not wait for permission — it arrives through those who are ready.
52%
FDA publishes heart-safety rules for ibogaine trials
The FDA (the US drug regulator) will write down specific rules about how companies must monitor people's hearts during ibogaine trials. This matters because ibogaine can affect heart rhythm in ways that could be dangerous, and right now there are no clear federal rules about what doctors have to check.
→ The FDA will publish specific heart-monitoring rules for ibogaine trials because the scientific evidence shows real heart risks that need standardized safeguards.
Resolves: 2027-06-30 · USA
REGULATION
the precise call ▾
FDA will issue formal guidance specifically addressing cardiac monitoring requirements for ibogaine and ibogaine analog trials by Q2 2027.. Accumulating QT/arrhythmia literature on ibogaine, combined with multiple active INDs, creates regulatory pressure to establish safety standards proactively. FDA has clear precedent for issuing compound-class guidance when cardiac signals emerge across multiple submissions. The 6-12 month delay esti
31%
FDA heart-safety guidance delays at least one ibogaine IND approval
The FDA will publish formal rules about heart monitoring for ibogaine, and at least one company running an ibogaine trial will later tell the FDA that this new guidance is the reason their trial got delayed. This is similar to the first prediction but focuses on whether the new rules actually slow down drug approvals.
→ New FDA heart-safety rules could delay ibogaine drug approval, though this specific outcome is harder to predict than the rules themselves.
Resolves: 2027-06-30 · USA
REGULATION
the precise call ▾
FDA will issue formal guidance on QT monitoring requirements for ibogaine by mid-2027, and this guidance will be cited as a primary reason for delay in at least one IND progress report filed before December 2027.. This is a duplicate of prediction #1 with a slightly different emphasis on IND delays. The cardiac literature signal is real. The question is whether FDA acts via formal guidance versus informal reviewer feedback or clinical hold letters, which are more common and faster. Formal guidance within 13 m
14%
SSRI washout rules mandated across multiple trials by mid-2026
Within 18 months, the FDA (or major drug companies running trials) will require people to stop taking SSRIs for a set period before joining MDMA or psilocybin trials. This will slow down enrollment because fewer people will be eligible, and the waiting period will be longer.
→ Mandatory SSRI washout rules would slow trial enrollment measurably, making recruitment harder and trials longer—but this outcome is unlikely in this timeframe.
Resolves: 2026-08-02 · Global
REGULATION
the precise call ▾
SSRI washout protocols will be formally required (via FDA mandate or sponsor-initiated amendments across at least five active trials) for MDMA and psilocybin INDs by August 2026, causing measurable enrollment delays at multiple sites.. Regulatory bodies move slowly; a formal mandate across all active trials within 3 months is historically unprecedented absent a clinical safety event. Sponsor-driven amendments are more likely but still require IRB and FDA concurrence. 'Measurable enrollment delays' adds an additional falsifiable ba
38%
Congressional hearing or federal probe triggered by ketamine clinic harm
Someone will be seriously hurt or die at an unregulated ketamine or psychedelic clinic in the US, the story will get attention, and Congress or a federal agency will hold a public hearing or launch a formal investigation. This matters because ketamine clinics are booming but barely regulated, and one high-profile disaster could reshape the whole industry.
→ Within a year, a serious injury at an unregulated clinic could trigger congressional or federal action—a meaningful but not certain risk.
Resolves: 2027-05-04 · USA
SAFETY
the precise call ▾
A serious adverse event at an unregulated U.S. ketamine or psychedelic clinic will be cited in congressional hearing testimony or trigger a formal federal investigation within 12 months of today.. Ketamine clinic expansion is rapid and largely unregulated at the federal level. Matthew Perry's death from ketamine in 2023 already demonstrated celebrity-case dynamics. The probability of at least one high-profile adverse event is moderate; the probability that it reaches congressional testimony o
28%
Trial protocols cite SSRI drug interaction research in washout rules
Ongoing psilocybin and MDMA clinical trials will publicly announce changes to their rules about how long people must stop taking SSRIs (common antidepressants like Prozac) before entering the trial. They'll do this because new research shows these drugs interact with psychedelics in ways that matter for safety.
→ Clinical trials will update their SSRI washout rules based on new interaction research, making protocols safer and more scientifically sound.
Resolves: 2026-09-30 · Global
RESEARCH
the precise call ▾
At least three published clinical trial protocol amendments for ongoing psilocybin or MDMA trials will cite SSRI/fluoxetine interaction data as justification for modified washout criteria by Q3 2026.. Preclinical fluoxetine-psychedelic interaction data has clear mechanistic relevance to ongoing trials. IRBs and sponsors monitoring the literature are obligated to assess protocol adequacy. However, the path from mouse data to published protocol amendments requires IRB review, sponsor approval, Clin